Muri, JonathanJonathanMuriCecchinato, ValentinaValentinaCecchinatoCavalli, AndreaAndreaCavalliShanbhag, Akanksha AAkanksha AShanbhagMatkovic, MilosMilosMatkovicBiggiogero, MairaMairaBiggiogeroMaida, Pier AndreaPier AndreaMaidaMoritz, JacquesJacquesMoritzToscano, ChiaraChiaraToscanoGhovehoud, ElahehElahehGhovehoudFurlan, RaffaelloRaffaelloFurlanBarbic, FrancaFrancaBarbicVoza, AntonioAntonioVozaDe Nadai, GuendalinaGuendalinaDe NadaiCervia, CarloCarloCerviaZurbuchen, YvesYvesZurbuchenTaeschler, PatrickPatrickTaeschlerMurray, Lilly ALilly AMurrayDanelon-Sargenti, GabrielaGabrielaDanelon-SargentiMoro, SimoneSimoneMoroGong, TaoTaoGongPiffaretti, PietroPietroPiffarettiBianchini, FilippoFilippoBianchiniCrivelli, VirginiaVirginiaCrivelliPodešvová, LucieLuciePodešvováPedotti, MattiaMattiaPedottiJarrossay, DavidDavidJarrossaySgrignani, JacopoJacopoSgrignaniThelen, SylviaSylviaThelenUhr, MarioMarioUhrBernasconi, EnosEnosBernasconiRauch, AndriAndriRauch0000-0001-5297-6062Manzo, AntonioAntonioManzoCiurea, AdrianAdrianCiureaRocchi, Marco B LMarco B LRocchiVarani, LucaLucaVaraniMoser, BernhardBernhardMoserBottazzi, BarbaraBarbaraBottazziThelen, MarcusMarcusThelenFallon, Brian ABrian AFallonBoyman, OnurOnurBoymanMantovani, AlbertoAlbertoMantovaniGarzoni, ChristianChristianGarzoniFranzetti-Pellanda, AlessandraAlessandraFranzetti-PellandaUguccioni, MariagraziaMariagraziaUguccioniRobbiani, Davide FDavide FRobbiani2024-10-252024-10-252023-04https://boris-portal.unibe.ch/handle/20.500.12422/164773Infection with severe acute respiratory syndrome coronavirus 2 associates with diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other immune factors are associated with adverse coronavirus disease 2019 (COVID-19) outcomes. Here we discovered that antibodies against specific chemokines were omnipresent post-COVID-19, were associated with favorable disease outcome and negatively correlated with the development of long COVID at 1 yr post-infection. Chemokine antibodies were also present in HIV-1 infection and autoimmune disorders, but they targeted different chemokines compared with COVID-19. Monoclonal antibodies derived from COVID-19 convalescents that bound to the chemokine N-loop impaired cell migration. Given the role of chemokines in orchestrating immune cell trafficking, naturally arising chemokine antibodies may modulate the inflammatory response and thus bear therapeutic potential.en600 - Technology::610 - Medicine & healtharticle10.48350/1796053687906710.1038/s41590-023-01445-w